Parnell names Sharon Holt vice president of U.S. pet care
Bottom line
Parnell has named Sharon Holt vice president of U.S. pet care, a leadership move the company says is aimed at accelerating growth in its companion animal business and strengthening support for veterinary customers. The appointment was announced September 22, 2026. Holt joins Parnell after more than 20 years in animal health, including leadership roles at Merial and, after its 2017 acquisition, Boehringer Ingelheim across sales, marketing, supply chain, commercial operations, and business development. In the new role, she will lead Parnell’s U.S. Pet Care business, with responsibility for commercial strategy, customer engagement, organizational development, and growth initiatives. (directoriosonline.marketminute.com)
Why it matters: For veterinary professionals, the hire signals continued investment in Parnell’s companion animal business at a time when the company has been expanding its anesthesia and sedation portfolio. Over the past two years, Parnell has added sedation products, launched a generic propofol injectable emulsion for dogs, expanded that line with a new 50 mL presentation, and added sevoflurane and a euthanasia solution for dogs. Earlier this year, Parnell also acquired Noble Pharma, a U.S.-based manufacturer, a move the company said would improve supply continuity and support growth across its product portfolio. Taken together, Holt’s appointment looks less like a routine executive change and more like part of a broader push to scale commercial execution in pet care. (parnell.com)
What to watch: Watch for whether Parnell pairs this leadership change with additional pet care launches, expanded field support, or tighter integration between commercial strategy and its growing U.S. manufacturing footprint. (directoriosonline.marketminute.com)
Parnell is reshaping its U.S. pet care leadership again, naming Sharon Holt vice president of U.S. pet care on September 22, 2026, as the company continues to build out its companion animal business. The company said Holt will oversee commercial strategy, customer engagement, organizational development, and growth initiatives for the U.S. Pet Care unit. (directoriosonline.marketminute.com)
The appointment comes as Parnell has been steadily expanding both its pet care portfolio and its U.S. operating footprint. Parnell’s recent press release history shows a clear run of companion animal activity: two new sedation products in May 2024, PropofolVet Multidose in January 2025, a pentobarbital sodium and phenytoin sodium euthanasia solution for dogs in March 2026, sevoflurane in June 2026, and a larger 50 mL PropofolVet Multidose presentation in July 2026. In April 2026, the company also announced its acquisition of Noble Pharma, adding a U.S.-based manufacturing asset that Parnell said would improve supply continuity and support future growth. (parnell.com)
Holt brings a long commercial background in animal health. According to Parnell’s announcement, she spent more than two decades in the sector, beginning at Merial in 2002 and continuing through Boehringer Ingelheim’s acquisition of Merial in 2017. Her experience spans sales, marketing, supply chain, commercial operations, and business development. Parnell also highlighted recent internal recognition she received at Boehringer Ingelheim, including the OnePet Innovation Award and Global Excellence Award in 2025, followed by the President’s Club Award in 2026. (directoriosonline.marketminute.com)
There’s also useful context in the role itself. Parnell had previously announced Dr. Chelsie Estey as vice president of U.S. pet care in March 2024, and outside coverage later reported that Estey moved to Hill’s Pet Nutrition as U.S. chief veterinary officer in March 2025. That suggests Holt is not filling a newly created function, but stepping into a leadership post that has already been central to Parnell’s companion animal strategy. (parnell.com)
Parnell framed the move as customer-focused. In the announcement, U.S. General Manager Pablo Lamberto, DVM, said Holt’s understanding of the companion animal market and focus on customer success and innovation made her “an outstanding addition” to the leadership team. The company’s broader messaging backs that up: Parnell describes itself as a veterinary pharmaceutical company focused on anesthesia and related animal health solutions, and its pet care materials emphasize distribution through major veterinary supply partners and education around anesthesia and sedation. (directoriosonline.marketminute.com)
Why it matters: For veterinary professionals, this is most relevant as a business signal. Leadership hires don’t change clinical practice on their own, but they can indicate where a manufacturer plans to invest. In Parnell’s case, the pattern points to deeper commitment in companion animal therapeutics, especially around anesthesia, sedation, and adjacent hospital-use products. If Holt helps sharpen commercial execution, clinics may see more consistent outreach, broader access through distributors, and potentially steadier supply as Parnell links its growing portfolio with newly expanded manufacturing capacity. That matters for practices trying to manage procedure flow, formulary choices, and pricing pressure without disruption. (directoriosonline.marketminute.com)
It may also matter because Holt’s background is unusually cross-functional for a commercial leader. Experience spanning supply chain, operations, and business development, not just sales and marketing, could be valuable in a veterinary market where availability, contracting, and customer support often shape product adoption as much as label claims do. That’s an inference based on her background and Parnell’s current expansion strategy, but it fits the company’s recent pattern of pairing product launches with operational buildout. (directoriosonline.marketminute.com)
What to watch: The next markers will be practical ones: new pet care product announcements, changes in field or distributor support, and any signs that Parnell is using its Noble Pharma acquisition to improve supply resilience in companion animal lines. If those pieces move in tandem, Holt’s appointment will look like part of a larger scale-up rather than a standalone executive update. (directoriosonline.marketminute.com)